218 related articles for article (PubMed ID: 24856894)
1. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
Hourd P; Ginty P; Chandra A; Williams DJ
Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
[TBL] [Abstract][Full Text] [Related]
2. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
Carpenter MK; Couture LA
Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
[TBL] [Abstract][Full Text] [Related]
3. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
4. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
[TBL] [Abstract][Full Text] [Related]
5. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
6. Towards Automated Manufacturing for Cell Therapies.
Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
[TBL] [Abstract][Full Text] [Related]
7. Putting a price tag on novel autologous cellular therapies.
Abou-El-Enein M; Bauer G; Medcalf N; Volk HD; Reinke P
Cytotherapy; 2016 Aug; 18(8):1056-1061. PubMed ID: 27288308
[TBL] [Abstract][Full Text] [Related]
8. Cell-based therapy technology classifications and translational challenges.
Mount NM; Ward SJ; Kefalas P; Hyllner J
Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20150017. PubMed ID: 26416686
[TBL] [Abstract][Full Text] [Related]
9. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
Ginty PJ; Rayment EA; Hourd P; Williams DJ
Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
[TBL] [Abstract][Full Text] [Related]
10. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the translation and commercialization of cell therapies.
Dodson BP; Levine AD
BMC Biotechnol; 2015 Aug; 15():70. PubMed ID: 26250902
[TBL] [Abstract][Full Text] [Related]
12. Addressing the Manufacturing Challenges of Cell-Based Therapies.
de Almeida Fuzeta M; de Matos Branco AD; Fernandes-Platzgummer A; da Silva CL; Cabral JMS
Adv Biochem Eng Biotechnol; 2020; 171():225-278. PubMed ID: 31844924
[TBL] [Abstract][Full Text] [Related]
13. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
14. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
15. Quality control system to support comparability assessment for the Renal Bio-Replacement therapy system.
Pitkin Z
Dev Biol (Basel); 2005; 122():131-8. PubMed ID: 16375257
[TBL] [Abstract][Full Text] [Related]
16. Challenges of translating a cell therapy to GMP.
Bauer G; Fury B
Int Rev Neurobiol; 2022; 166():207-234. PubMed ID: 36424093
[TBL] [Abstract][Full Text] [Related]
17. Technological developments for small-scale downstream processing of cell therapies.
Buckler RL; Kunkel EJ; Thompson ML; Ehrhardt RO
Cytotherapy; 2016 Mar; 18(3):301-6. PubMed ID: 26857225
[TBL] [Abstract][Full Text] [Related]
18. Regulatory issues in cell-based therapy for clinical purposes.
Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
[TBL] [Abstract][Full Text] [Related]
19. Regulatory perspectives from Japan - comparability of biopharmaceuticals.
Kawanishi T
Biologicals; 2006 Mar; 34(1):65-8. PubMed ID: 16330220
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
